#1evotec The Data-Driven R&D Autobahn to Cures Global leadership in data, science, multimodality & access Evotec SE, Company Presentation, July 2022 #RESEARCHNEVERSTOPS пл 11111101001 00#2evotec Disclaimer This presentation (including any information which has been or may be supplied in writing or orally in connection herewith or in connection with any further inquiries) is being delivered on behalf of Evotec SE (the "Company", "we," "our" or "us"). This presentation is made pursuant to Section 5(d) and/or Rule 163B of the Securities Act of 1933, as amended, and is intended solely for investors that are qualified institutional buyers or certain institutional accredited investors solely for the purposes of familiarizing such investors with the Company. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy Evotec securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No representations or warranties, express or implied, are made as to the accuracy or completeness of the statements, estimates, projections or assumptions contained in the presentation, and neither the Company nor any of its directors, officers, employees, affiliates, agents, advisors or representatives shall have any liability relating thereto. Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Many of the forward-looking statements contained in this presentation can be identified by the use of forward-looking words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and other similar expressions that are predictions of or indicate future events and future trends, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. The forward-looking statements contained in this presentation speak only as of the date of this presentation, and unless otherwise required by law, we do not undertake any obligation to update them in light of new information or future developments or to release publicly any revisions to these statements in order to reflect later events or circumstances or to reflect the occurrence of unanticipated events. PAGE 1 Non-IFRS Measures This presentation contains references to certain non-IFRS measures including EBITDA and Adjusted EBITDA, each of which are not recognized under International Financial Reporting Standards ("IFRS”). The Company believes that non-IFRS financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance and assists in comparisons with other companies, some of which use similar non-IFRS financial information to supplement their IFRS results. The non-IFRS financial information is presented for supplemental informational purposes only, and should not be considered a substitute for financial information presented in accordance with IFRS, and may be different from similarly titled non-IFRS measures used by other companies. EBITDA and Adjusted EBITDA each have limitations as an analytical tool, respectively, and you should not consider any of these measures either in isolation or as a substitute for other methods of analyzing the results as reported under IFRS. Our management team uses these non-IFRS financial measures to evaluate our profitability and efficiency, to compare operating results to prior periods, and to measure and allocate financial resources internally. However, management does not consider such non-IFRS measures in isolation or as an alternative to measures determined in accordance with IFRS. See appendix to this presentation for a reconciliation of Adjusted EBITDA to the nearest GAAP measure.#3PAGE 2 evotec Agenda Unique business strategy and capabilities to improve efficiency Precision medicine platforms to improve probability of success Building a strong growth business and a large royalty pool#4evotec PAGE 3 Agenda Unique strategy and capabilities to improve Efficiency & Probabilities of Success QUANTUM LEAP PF! BRAGGER. AA I 1 P#5evotec lekialakalda Alca Almaske). LEGACG GHG CxG C+C PAGE 4 GC Kron+ m₂ kuu t In Vi таким IG * · C Bringing the industry closer together Our contribution to the industry „The goal of Evolution is not one single human, it is mankind." Manfred Eigen 1927-2019, Co-founder of Evotec, Nobel Prize 1967 We design medicines for difficult to treat diseases in efficient collaborations We focus on data driven precision medicine and early disease relevance to improve Probabilities of Success We built the "shared economy" in R&D, designed to result in a large royalty pool#6evotec Industry needs PAGE 5 11011016 110110100101 Y R&D efficiency platforms¹) Precision medi- cine platforms Just - Evotec Biologics¹) Platforms & technologies are high-tech driven & fully integrated The drug discovery & development innovation hub - Capabilities & expertise overview Right modality drug design Capabilities & Expertise (illustrative) JUU Hit Target ID & Lead validation identification optimisation management Sample EVOpanOmics ScreenSeq HIGH-THROUGHPUT TRANSCRIPTOMICS J.DISCOVERY™ MOLECULE DISCOVERY EVOcells EVOgenes Chemistry 900€ J.HALSM AD EVOpanHunter Screen Pep HIGH-THROUGHPUT PROTEOMICS Antibodies & Bifunctionals DMPK & Bio In vitro In vivo Biomarker Research ADME-Tox informatics Reagents biology Pharmacology discovery discovery AI DESIGNED MAB LIBRARY Small molecules a.d ¹) Also partly accessible as stand alone "Fee for Service" or FTE-rate based offerings EVOgnostic J.MD™ MOLECULE DESIGN Antisense Protein degradation E.MPD TRANSLATIONAL MOLECULAR PATIENT DATABASE JP3Ⓡ ܥܠܘ Antibody INDIGO Integrated Integrated CMC Exosomes E.IPSC DRUG DISCOVERY PROCESS & PRODUCT DESIGN Clinical pre-clinical development development solution E.RNA TARGETING RNA SPACE E.SAFETY Tox AND SAFETY PREDICTION J.PODⓇ MANUFACTURING DESIGN E.INVENT-AI MOLECULAR DESIGN EXCELLENCE#7(101 PAGE 6 evotec 1401101011 14011 底 h 62 Patent applications >10 Precision platforms >15 Biologics projects Faster and more learning curves illustrate ... “just the beginning" "Evotec inside" (selected KPI's 2020/21) >130 Co-owned pipeline assets 142 High-throughput screens >200 bn Data points 20 Months construction time >90 Small molecules 12 Pre-clinical development candidates (PDC) >440 bn of iPSC-derived cells >40,000 samples in HT analytics and functional characterisation >20 Biologics 24 INDIGOⓇ programs >10,000 compounds assessed as protein degraders >20 consecutive successful manufacturing runs >10 Cell & gene therapy > 250 GMP API batches >100 EVOPanHunter projects >90% J.POD® cGMP qualification activities completed >10 Multiple modalities#8evotec Partners > 40 Pharma > 400 Biotech > 30 Academia > 10 Foundations PAGE 7 We establish the “sharing economy" in R&D Our network of > 500 partners Collaboration priorities Flexible access to technologies and assets Integrated drug discovery & development processes Funding & operations for industrial translation Data pooling & advanced analytics of patient data evotec More efficient & more precise drugs#9evotec Key challenges R&D model is inefficient "One drug fits all" is outdated New modalities did not solve all problems Emerging technologies are still very fragmented PAGE 8 Bringing Probability of Success up is key leverage for better IRR¹) Current challenges in R&D Challenging returns due to "too late and "expensive failure" 90% of drugs are efficacious only in 50% of patients 9% of Phase I biologics receive approval²) Precision medicine toolkit, OMICS platforms, and AI/ML Development costs per asset increase Cost per asset doubled since 2010, in US$ m ~2,500 1,188 2010 2020 Commercial returns decrease IRR since 20104) ~10 2010 ~23) 2020 ***** ***** ¹) IRR = Internal Rate of Return 2) https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2021/files/reports/2021-clinical-development-success-rates-2011-2020-v17.pdf 3 excl. Covid-19 vaccines 4) Sources: Deloitte - Centre for Health Solutions: Ten years on measuring the return of pharmaceutical innovation 2020; Evaluate Pharma - World Preview 2018 / World Preview 2020 Pos UP +100% -80% *da ... 9.g. 30 ... 30².. 10 0.0 @*** 682 * 34. .08. .... ::** B...#10evotec Multiple sources to drive innovation Single cell tech- nologies Safety prediction Spatial multi-Omics PAGE 9 RNA analytics Al-derived biologics iPSCs Linking genetic, Structures & Functions Mass Spectro- metry CRISPR- based Dx/Tx Cell Tx Integrating and accelerating better data for more precise medicine What does 'data-driven' mean in practice? Gene Tx Al-enabled small molecules Molecular databases Quantum simulation Small molecule RNA-binders 10 110110110010 110116096 1101101001101 TTED ENK 104-1 R&D efficiency platforms Precision medicine platforms Just - Evotec Biologics Right modality drug design EVOIR&D EVOpanOmics & EVOpanHunter EVO access EVOmodality Data integration evotec Precision medicine Data aggregation#11evotec Many players at work to initiate a new "data driven" industry paradigm PAGE 10 Still a highly fragmented industry Selected AI/ML companies (Industry landscape - Illustrative & highly simplified) Data integration Patient outcomes Academic data ELEVATE IKTOS mission bio "T'EMPUS Fote THERAPEUTICS IMIDomics celmatix AbCellera Schrödinger Google Early Discovery S Sensyne Health CENT GENE THE RARE DISEASE COMPANY ✔ Atomwise B BERG insitro Benevolent* Exscientia RECURSION deep genomics evotec +tellic C (intel) Pfizer AiCure® novo nordisk DV flatiron. FDNA TELEHEALTH BIOFORTIS a Q² Solutions Company BS MEDIDATA EULARIS Roche PPD SWORD HEALTH CytoReason Approval and post-approval IQVIA Data aggregation#12evotec Todays use of AI/ML Significant improvements of PoS are possible How we can improve PoS in early R&D (Examples/simplified) Target identification System biology to better understand diseases e.g. associating existing targets with new diseases Lead optimisation In silico classification of targets via computational chemistry e.g. better prioritised drugs accelerated PAGE 11 Trial design Understanding sub populations via biomarkers e.g. better patient stratification Data integration in % d... 21... ..... 08. *... 20 *98* ~10% Pos up .. Integrated drug design .... .. ...... @ .*.*** 9. e bes 20. 8. at 88 Ⓒ... @ ***** tonce. ****** ... ****... *8? 100.. @* ** ~10% ... a Efficacy & safety predictions ~10% iPSC driven disease relevance ~10% Molecular data & patient stratification 'Standard' success for discovery project Data aggregation#13evotec PAGE 12 Agenda Precision medicine platforms to improve probability of success#14evotec Molecular patient databases Re-defining health and disease via molecular disease profiles EVOpanOmics EVO panHunter PAGE 13 E.IPSC DRUG DISCOVERY Precision medicine is the only path to improved medicine Leading AI/ML driven drug discovery & development platforms Targeted disease models & precision medicine approaches Focus on early disease relevance Clinical diagnostics and biomarkers Precision diagnostics and tracking of diseases • Transcriptomics and proteomics data at industrial scale Multiple patient-derived data bases, e.g. CKD database (>10,000 patients; >600 billion data points) • User friendly AI/ML driven multi-omics analysis platform • Exceeding industry standards in predicting drug safety (e.g.: liver injury 86% vs. 70%) One of the largest and most sophisticated iPSC platforms for drug discovery in industry • First iPSC-derived drug candidate in clinic, large pipeline evolving in drug discovery and cell therapy -I-#15PAGE 14 evotec Lung & Multiple cancers Womens' Health Deep understanding of biology for precision medicine The Evotec Molecular Patient Database (E.MPD) Kidney diseases CNS Multiple rare diseases Tuber- culosis Go Liver disease Patient databases with clinical and molecular profiles EVOpanOmics: Genomics, Transcriptomics, Proteomics and Metabolomics EVOpanHunter: Bioinformatics, AI/ML Infectious diseases EVOpanOmics EVOpanHunter Data generation Data analysis INFECTIONS Autoimmune disease S Fibrosis E.MPD TRANSLATIONAL MOLECULAR PATIENT DATABASE Inflammation#16evotec A BAYER 2016/17 • Upfront ● • Research funding • Milestones > € 300 m per product • Tiered royalties PAGE 15 E.MPD core component of alliances in CKD CKD strategic drug discovery deals V VIFOR PHARMA 2018/19 • Vifor funded: € 25 m • 50% on all projects • JV: NepThera Neph Thera novo nordisk 2020 Ⓡ Upfront • Research funding • Milestones > € 150 m per product • Tiered royalties Pending acquisition by CSL Limited not closed, yet CHINOOK THERAPEUTICS 2021 Upfront • Research funding From Target identification & validation, via biomarker identification, to patient stratification • Milestones • Tiered royalties Lilly 2022 Upfront • Research funding • Milestones US$ 180 m per product • Tiered royalties#17evotec Proteomics approach to targeted protein degradation Development of novel therapies for a broad range of diseases PAGE 16 Protein degradation partnership with BMS becomes strategic Using EVOpanOmics & EVOpanHunter - Quantum Leap in 2022 evotec & ll Bristol Myers Squibb May 2020 Screening milestone Mar 2021 Double-digit million extension 2018 Upfront US$ 65 m • Potential milestones 2019 > US$ 250 m per project • Double-digit royalties Oct 2020 Project initiation June 2020 US$ 10 m - Expansion 2020 Dec 2020 Second project initiation June 2021 New collaboration in undisclosed therapeutic area 2021 May 2021 Third project initiation May 2022 8-year extension Upfront $ 200 m Deal value > $ 5bn 2022#18evotec PAGE 17 Deal value in $bn 5.0 2.5 2.0 1.5 1.0 0.5 BMS & Evotec create the globally leading TPD¹) alliance Analysis of selected licensing deals – strong momentum in the last 2 years - 0 Size of bubble denotes breadth of pipeline Amphista/ BMS Nurix/ Sanofi Lycia/ Lilly Amphista/ Merck Discovery 1) Targeted Protein Degradation Source: Company webpages, Evotec analysis evotec Bristol Myers Squibb Seed/ Lilly Plexium/ Amgen Vividion/ Bayer Pre-Clinical Arvinas/ Pfizer Kymera/ Sanofi Clinical Foghorn/ Lilly#19evotec Global precision medicine market¹) in US$ bn Global cell therapy market²) in US$ bn Global induced pluripotent stem cell (iPSC) Market in US$ bn PAGE 18 63 2020 7.8 2020 1.6 2020 Transformative iPSC-based disease modelling & cell therapy Industry leading iPSC platform 107 2025 15.7 2025 2.3 2025 CAGR ~11% CAGR ~15% CAGR ~7% "IPS cells are a powerful tool to cure intractable diseases because they can be made from patients' somatic cells." Shinya Yamanaka, Nobel prize laureate DRUG DISCOVERY Disease-specific drugs "Disease in a dish" & Screening Patient or healthy donor iPSC platform ¹) https://www.gminsights.com/ Feb 2020, Evotec estimates 2) https://www.grandviewresearch.com/industry-analysis/cell-therapy-market, Evotec estimates https://www.researchandmarkets.com/reports/4805485/induced-pluripotent-stem-cell-ipsc-global CELL THERAPY ¡PSC-derived cell types 000 ooo AAS Off-the-shelf cell therapeutic "Evotec's iPSC platform with the goal to industrialise iPSC- based drug screening" Largest and most sophisticated iPSC platform in the industry >300 patient-derived cell lines across 15+ disease areas Optimized for high reproducibility, high throughput and robustness First IPSC-derived drug candidate entered clinical trials in 2021#20evotec iPSC alliance in neurodegeneration • Development of novel therapies for a broad range of neuro- degenerative diseases • First programme EVT8683 (elF2b activator) started clinical development 2021 • Phase I read-out expected in 2022 PAGE 19 Proving paradigm shift in iPSC-based discovery BMS alliance Using EVOpanOmics & EVOpanHunter - Development since 2016 2016 evotec & 2017 US$ 5 m - Screening milestone Upfront US$ 45 m • Potential milestones 2017 > US$ 250 m per project • Double-digit royalties ll Bristol Myers Squibb Oct 2018 US$ 6 m - Expansion milestone May 2018 US$ 6 m - Expansion milestone 2018 Sep 2019 US$ 30 m - Extension Dec 2018 US$ 14 m - Lead optimisation payment Sep 2020 US$ 6 m - Expansion milestone 2019 Jan 2020 US$ 6 m - Expansion milestone Sep 2021 US$ 20 m 1st IND Target: elF2b 2020 Dec 2020 US$ 6 m - Expansion milestone Nov 2021 US$ 40 m - Designation of additional programmes 2021 Oct 2021 US$ 9 m - Expansion milestone#21iPSC Platform evotec ¡PSC-based cell types ● PAGE 20 ¡PSC-based cell types gene editing ArrayCGH, karyotyping, WGS ________ ம் IT TOTOO ID www.wand BILD O THE DITE) www UDEILD XX Xx Delivering off-the-shelf cell therapy products to patients EVOcells - seamless R&D continuum integrating discovery, development and manufacturing X INDED F 0 QC & upscaling disease expertise NU NOM XL Pre-clinical development & CMC Single cell sequencing 3D expansion Evotec Clinical manufacturing Partner Clinical development Upscaling ******** Cell QC pluripetency FACE Sede d Cat concentration Markers PCR Germer 5 Marker geres und pee Cleste merhaay an only Calco CC ww OPCH Organ Mebl Marker ge Custer morphology Cel concentration agreed Fre Comtrent FACE 4 Maker poing OPCR Marker ge End stage ty Cluster my ofen Cel concentration • Most advanced programme: E.iBeta - ¡PSC-based islet-like clusters mimicking human islet cells • Partnership with Sernova - iPSC-based beta cell replacement therapy for insulin-dependent Diabetes using Sernova's Cell Pouch™, an implantable medical device for immune protection of E.iBeta Filing of first IND expected in 2024 • Addition of Evotec (Modena) Srl, our Evotec Cell Accelerator, secures reproducible and cGMP-compatible production of E.iBeta batches and represents the broadest and most widely integrated cell therapy platform in the industry Marked supply Marketing and sales cGMP production#22evotec Partners e.g.: PAGE 21 Enabling global access to modern biologics Efficient and flexible biologics manufacturing (EVOaccess) Large and diverse library to generate antibodies J.HALM J.DISCOVERY™ MOLECULE DISCOVERY AI DESIGNED MAB LIBRARY Modular, flexible "PODS" with most J.PODⓇ capital efficient set-up J.DESIGN MERCK MANUFACTURING DESIGN U.S. Department of Defense J.MD™ TM MOLECULE DESIGN JP3Ⓡ PROCESS & PRODUCT DESIGN Reviews and improves native antibody sequences to enhance manufacturability and stability Disruptive, intensified production process from a few kilograms to metric tons in the same facility BILL & MELINDA GATES foundation#23evotec Fully end-to-end continuous process for late-stage products (>25-day production) J.PODⓇ - MANUFACTURING DESIGN 500L SUB PAGE 22 Perfusion skid Surge Continuous process outperforming fed batch 20x Example: More intensification, higher productivity, lower COGMS Multi-column Pro A capture Low pH Viral Inactivation Depth Filtration 1) DS = Drug Substance Surge FT Polishing Chrom Surge Viral Filtration Surge Inline Conc/ Inline DF DS pool Kg DS¹) per Bioreactor 40 35 30 25 20 15 10 5 0 500L 1,000L Fed batch Hybrid 15d E2E 25d#24evotec Building business PAGE 23 Agenda a strong growth and a large royalty pool#25evotec Industry needs PAGE 24 11011016 110110100101 Y R&D efficiency platforms Precision medi- cine platforms Just - Evotec Biologics We create long-term value through three collaboration routes Service fees, milestones, and royalties for optimal value mix Multimodality drug design A "Fee-for-service" EVOcells EVOgenes B EVOroyalty Antibodies & Bifunctionals Small molecules Antisense C EVO equity Protein degradation Exosomes RNA#26evotec Attraction 283 PAGE 25 2019 +25% 100 +23% 80 mmm 60 40 20 0 2019 2020 No. of customers > € 1 m revenues 315 2020 New customers during the year 355 2021 • Customer base more diversified; revenues have grown significantly A "Fee-for-service" Significant expansion of alliances is basis for long-term success Attraction, Extension, Retention Extension 2021 Integrated drug discover & development offering yields increasing "share of wallet" Structural Retention ≥90% Faster and better results versus in-house infrastructures 100% 80% 60% 40% 20% 0% 2019 Customer relation rate 2020 2021 • Solid customer retention rates • Strong basis for double-digit growth#27evotec Small molecules Biologics Cell and Gene therapy Multiple modalities²) PAGE 26 B EVOroyalty Building a robust, de-risked pipeline within EVOroyalty High-value partnerships offer path to increased royalties Pipeline assets in 2021 > 90 > 20 > 10 > 10 Number of projects¹) 49 2015 1) Excluding EVOequity 2) For these projects multiple modalities are currently being explored >130 2021 >170 2025 goal#28Clinical Preclinical Discovery evotec PAGE 27 Ph3 Ph2 IP2X3 - CC Ph1 Jingxin Bayer Bayer ND ND ND ND ND ND ND ND ND ND ND Partnered Pipeline Neuroscience & Pain P2X3 - OAB ₁ Centrexion Bayer ND ND EVT ND ND ND ND ND ND P2X3 - DNP BMS EVT EVT EVT EVT EVT EVT Bayer - B1 Exscientia Aeovian Despite P2x3 set back - The iceberg keeps growing >220 projects including EVOequity and BRIDGEs: ~180 in partnerships, >40 internal R&D Facio Exscientia Argobio LAB282 LAB282 B EVOroyalty Autobahn Facio Cajal Neuro Exscientia EVT CureXsys Unpartnered Pipeline LAB282 LAB150 BI/Xynomic Exscientia Kazia Sanofi/ Apeiron ND ND EVT EVT EVT ND ND ND ND ND ND ND ND ND ND EVT EVT/MF EVT/MF EVT/MF EVT/Indiv EVT EVT ND Oncology EVT EVT Carrick EVT EVT EVT EVT EVT EVT Carrick Carrick Carrick Exscientia Exscientia Autobahn Immunitas Exscientia Breakpoint Autobahn Breakpoint Blacksmith Immunitas Quantro Ananke Autobahn Exscientia OxVax Carrick DarkBlue LAB282 Danube Labs BELAB1407 BELAB2122 Bridges Pipeline LAB282 LAB150 Argobio Metabolic Diseases Bayer ND QRbeta ND EVT ND ND ND ND ND ND ND EVT E.IBETA EVT EVT EVT ND ND ND EVT EVT EVT EVT N=4 Equity Pipeline 1) Also includes Women's Health, Respiratory projects The Equity Pipeline does not contain programs from EVT/partners that are not publically disclosed Eternygen Neph Thera LAB282 Neph Thera EVT EVT EVT EVT LAB282 LAB150 Neph Thera IP2X3 - Endo Bayer Conba ND Topas ND ND ND ND ND Inflammation & Immunology¹) EVT Bayer Fibrocor Topas Exscientia Topas Celmatix ND ND Autobahn Celmatix CureXsys Exscientia Fibrocor LAB150 LAB282 Topas Topas Exscientia LAB150 LAB282 Fibrocor Celmatix Blacksmith Fibrocor Sanofi ND ND Virology ND ND ND ND ND ND LAB282 ND Exscientia LAB282 Anti-bacterial Nosopharm ND Myxob ND ND ND ND Forge Forge Forge Forge Exscientia Global Health SK bioscience ND ND ND ND ND ND ND ND ND#29evotec B EVOroyalty PAGE 28 "Evotec Inside" Steady stream of high-value catalysts Selected pipeline events within next 12 - 24 months Phase III & registration (CHN) JingXin in insomnia (EVT201) • Phase II data with Bayer in DNP (BAY2395840) • Phase II initiation with Bayer in Gynaecology (BAY2395840) • Phase I data in Chikungunya virus (EVT894) ● Phase I data with BMS in CNS (EVT8683) • Phase I data with Kazia in Oncology (EVT801) • Phase lb/II initiation of Exscientia in Oncology (EXS21546) • Phase I initiation in Covid-19 / HBV (EVT075) • Phase I Initiation with Bayer in Kidney diseases • Phase I Initiation with Kidney diseases with other partners • Phase I initiation with BMS in CNS • Phase I Initiation with BMS in Oncology Multiple co-owned equity companies (not outlined here) will progress in clinic (e.g. Topas, Forge, Carrick, Fibrocor, ...) DNP: Diabetic neuropathic pain CNS: Central nervous system Clinical Pre-clinical Discovery Molecule EVT201 Not Disclosed BAY2395840 CT7001 XP-105 EVT401 BAY2328065 EXS21546 CNTX 6016 EVT894 Not Disclosed Not Disclosed EVT801 EVT8683 TPM203 CT7001 CT7001 APN411 GLPGXXXX BAYXXXX QRB001 EVT075 Not disclosed EVTXXXX Therapeutic Area/Indication Insomnia (GABA-A) Infectious Disease (Antibody) Diabetic Neuropathic Pain (B1) Oncology (CDK7) Oncology (mTORC1/2) Immunology & Inflammation (P2X7) Gynaecology Oncology (various programmes) Pain (CB2) Chikungunya (Antibody) Neuroscience & Pain Neuroscience & Pain Oncology (VEGFR3) Neurodegeneration (elF2b activator) Pemphigus Vulgaris (ND) Oncology (CDK7) Oncology (CDK7) Oncology - Immunotherapy Fibrosis (not disclosed) Nephrology (not disclosed) Metabolic Diabetes (not disclosed) Covid-19/ HBV Various programmes CNS, Metabolic, Pain, ... Partner 京新药业 NGAN PHARMACEUTICAL DE SK bioscience Carrick. therapeutics XYNOMIC Pharma • 康恩贝集团 CONRA GROUP Exscientia DRIVEN BY KNOWLEDGE CENTREXION THERAPBUTIES NIH) SANOFI n.a. n.a. KAZIA Bristol Myers Squibb™ Topas Therapeutics Carrick Carrick SANOFI Galápagos QRbeta THERAPEUTICS n.a. APEIRON BIOLOGICS Bristol Myers Squibb >10 further programmes Discovery Pre-clinical Phase I Phase II Phase III Multiple programmes across nephrology, oncology, immunology among other therapeutic areas#30evotec PAGE 29 Academia & BRIDGES External deal- flow Partners Starting points to fuel EVO equity portfolio Portfolio companies C EVO equity EVO equity accelerates co-owning strategy Operational VC model - diversified portfolio with multiple shots on goal Evotec spin- outs Attractive portfolio with significant upside At Equity Holding (≥20%) or Significant influence Eternygen celmatix therapeutics BIOCAPITAL Minority Shareholdings (<20%) Carrick BRIDGES .... Topas Therapeutics mission Cajal Neuroscience LAB282 DARK BLUE https://actionplan.evotec.com/evoequity THERAPEUTICS Exscientia LAB150 facio AUTOBAHN therapies LABS CUREXSYS PURE 8 CURE AUTOBAHN FORGE Therapeutics a LABS DANUBE LABS FIBROCOR panCELLa BLACKSMITH ARGOBIO Immunitas THERAPEUTICS Medicines STUDIO AeoVian PHARMACEUTICALS ARGOBIO STUDIO BREAKPOINT THERAPEUTICS QUANTR oxvax Therapeutics TUBULIS IMIDomics Ananke Therapeutics beLAB2122 NephThera LEON ENABLING NANO NOW Centauri THERAPEUTICS Sernova Corp beLAB1407#31evotec Group revenues (at constant fx-rates¹)) Unpartnered R&D²) Adjusted EBITDA³) (at constant fx-rates) PAGE 30 Significant growth step up and investments towards AP 2025 Guidance 2022 Guidance 2022 € 700 - 720 m (€ 690 – 710 m) € 70 - 80 m € 105-120 m (€ 95 - 110 m) YE 2021 ¹) EUR/US$ 1.18; EUR/GBP 0.86 2) No material FX effects as most R&D efforts are carried out in € area 3) Considerable insecurities given high volatility of energy prices € 618.0 m € 58.1 m € 107.3 m Implied growth at midpoint ~15% ~30% Approx. € 300 m investment programme for enabling and supporting growth (e.g. capacity expansion, ...) At least stable#32evotec Targeted revenue development (in € m) CAGR ~15% PAGE 31 501 2020 618 2021 Clear strategy in place Growth and investment strategy overview - Action Plan 2025 2022 (e) 2023 (e) 2024 (e) >1,000 2025 (e) Revenue composition 2020 EVT Execute Just - Evotec Biologics¹) EVT Innovate Goal revenue composition ¹) Just - Evotec Biologics reports under the EVT Execute segment EVT Execute Just - Evotec Biologics¹) EVT Innovate ~20% ~10% >25% ≥2x >30% ~70% >40% ● Composition of revenue mix expected to change over time while ALL fields continue to grow Shifting to even more favourable revenue mix expected to drive increased profitability • Just Evotec Bio- logics growth driven by use of J.PODⓇ manufacturing • First small royalties from pipeline assets expected in 2025#33PAGE 32 evotec Setting the pace to accelerate growth along Action Plan 2025 Selected major newsflow 2022 R&D efficiency platforms Precision medicine platforms Just - Evotec Biologics Group & ESG ● ● ● ● ● ● ● Undisrupted growth of base business, in-line with AP 2025 (EVOIR&D) New integrated drug discovery & development alliances Significant capacity and value chain expansion for all modalities New strategic partnerships and expansions of co-owned alliances New clinical trial initiations Significant progress of later stage co-owned pipeline (EVOroyalty) Spin-Offs and investments along Building Blocks of AP 2025 (EVO equity) Start of production J.POD® Redmond, WA (US) Start of construction J.POD® Toulouse, France (EU) Evaluation of global network of J.PODSⓇ (EVO access) Undisrupted growth trend versus 2021 in line with AP 2025 Growth of unpartnered R&D investments faster than top-line Validated science-based targets aligned with 1.5°C goal Highly impactful contribution to UN SDG 3¹) ¹)UN Sustainable Development Goal 3: Improve health and well-being with main targets for us on women's health, fight against infectious diseases and pandemic preparedness#34evotec Upcoming important dates Financial calendar 2022 Quarterly Statement Q1 2022 Virtual Annual General Meeting 2022 Half-year 2022 Interim Report PAGE 33 Quarterly Statement 9M 2022 11 May 2022 22 June 2022 11 August 2022 09 November 2022 evotec ***** #RESEARCHEVERSTORE SETTING THE PACE evotec STAINABILITY REPORT THE Evotec SE SUSTAINABILITY REPORT 2021 #REARNEVERSTOPE#35evotec Appendix#362009 Action Plan 2012 Restructure for growth evotec ● 2010 • Revenues: € 55 m • Adj. EBITDA: € 2 m • R&D investments:¹) € 2 m • Co-owned projects: 6 Employees: 519 PAGE 35 2012 Action Plans deliver significant value Action Plans in numbers - " Action Plan 2016 Build innovation seeds 2015 • Revenues: € 128 m • Adj. EBITDA: € 9 m • R&D investments:¹) € 18 m • Co-owned projects: 49 Employees: 1,000 ● ¹) Including equity investments ... 2018 we are just at the beginning" Action Plan 2022 Aspire global leadership 2021 2020 • Revenues: € 501 m • Adj. EBITDA: € 107 m • R&D investments:¹) € 69 m • Co-owned projects: 118 • Employees: 3,572 Action Plan 2025 Leadership in data, science, multimodality & access 00 11111101001 00 ACTION PLAN 2025 The data-driven R&D Autobahn to Cures 2025#37USA >500 • Branford • Princeton ● evotec Redmond, WA • Seattle • Watertown PAGE 36 1st J.PODⓇ: Redmond Platforms & technologies for more precision and efficiency Evotec today - 16 Sites & more than 4,300 employees US Austria ~40 • Orth an der Donau AT ● IT • Modena Italy >850 • Verona (Campus Levi-Montalcini) DE UK J.POD® Redmond, WA (US) Germany >1,050 Hamburg (HQ) & Goettingen (Manfred Eigen Campus) Cologne • Munich FR UK >950 • Abingdon (Dorothy Crowfoot Hodgkin Campus) Alderley Park France >900 • Lyon • Toulouse (Campus Curie) 2st J.PODⓇ: Toulouse#38evotec Interdisciplinary . Biochemists • Medicinal chemists • Molecular biologists • Cell biologists Highly qualified 76% with at least one academic qualification PAGE 37 Great talent pool Overview Employees - more than 4,200 • Toxicologists • Data scientists • Process/Analytical chemists • Clinicians • mAb process engineers 24% other degrees 1) The chart exclude the USA for legal reasons International¹) 22% Others 20% German 21% French Diverse and experienced • 81 nationalities • >30% PhDs Average age: 38.5 years 19% Italian 18% British • 54% women . > 36% with more than five years at Evotec#39evotec Best possible environment for employees and potential recruits • Engagement & commitment • Leadership & training ● Diversity, Equity & Inclusion Our purpose is to go VERY long as ONE - #researchneverstops Sustainable thinking is holistic and ensures long-term success Acknowledging Principles for Responsible Investment PAGE 38 QUALITY 4 EDUCATION Resilient business model • Financial resilience & independence • Constant investments into the future • Basis for sustainable success • Compliance with investors' sustainable investment criteria • Source for funding resilient growth DECENT WORK AND ECONOMIC GROWTH GENDER EQUALITY 19 RESPONSIBLE CONSUMPTION AND PRODUCTION Profit 1) "Science Based Targets Initiative" People Partner Purpose #RESEARCHNEVERSTOPS PRI Planet Pa- tients The "shared economy" in R&D • Integrated platform with >800 partners • Sharing values of highest integrity • Sharing success POVERTY Protecting the planet • Commitment to SBTi¹) • Responsible use of resources GOOD HEALTH 3 AND WELL-BEING Cures for all / Access for all • We will not stop until all existing diseases can be cured • Precise, patient-centric medicine Respecting diversity in all dimensions CLEAN WATER AND SANITATION 9HDUSTRYMMATION ANDINFRASTRUCTURE CLIMATE 13 ACTION GENDER EQUALITY 12 RESPONSIBLE 12 CONSUMPTION AND PRODUCTION CO ONLAND#40>9% T. Rowe Price Group evotec < 10% Novo Holdings A/S 2 68% Free float PAGE 39 52 week high/low: € 45.70/€ 21.12 Strong team and shareholders supporting sustainable growth Management & shareholder structure¹) 2 ~ 7% Mubadala Investment Company < 5% Roland Oetker/ROI Number of shares: 177.0 m Listings: Frankfurt Stock Exchange (MDAX, TecDAX), Ticker: EVT NASDAQ Global Select Market (ADS), Ticker: EVO ~1% Management 1) Rounding differences may occur Management Board • Werner Lanthaler (CEO) Long-time experience in Pharma & biotech • Cord Dohrmann (CSO) Long-time experience in drug discovery • Matthias Evers (CBO) Long-time experience in business development, technology and strategy ● Craig Johnstone (COO) Strong drug discovery and commercial track record • Enno Spillner (CFO) Long-time experience in finance & biotech Supervisory Board • Iris Löw-Friedrich UCB • Camilla Macapili Languille Mubadala Investment Co. • Mario Polywka Ex-Evotec • Roland Sackers QIAGEN • Elaine Sullivan Ex-Lilly • Constanze Ulmer-Eilfort PSP Munich#41evotec Your contact: Volker Braun Global Head of Investor Relations & ESG +49.(0).40.560 81-775 +49.(0).151 1940 5058 (m) [email protected] #RESEARCHNEVERSTOPS